SCHEDULE 13G/A: RA Capital Management Affirms 9.9% Passive Stake in Unicycive Therapeutics

RA Capital Management, L.P. and its affiliated entities have filed an amended Schedule 13G, confirming their continued passive beneficial ownership of 9.9% in Unicycive Therapeutics, Inc. as of December 31, 2024.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") filed an Amendment No. 3 to Schedule 13G.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 11,520,120 shares of Unicycive Therapeutics, Inc. Common Stock.
• This ownership represents 9.9% of the class, which was rounded down from 9.99% due to limitations of the EDGAR filing system.
• The beneficial ownership includes shares issuable upon conversion of Series A-3, A-4, and A-5 Convertible Preferred Stock, which are held through Tranche A, B, and C Warrants.
• A "Beneficial Ownership Blocker" is in place, precluding the conversion of Preferred Stock to the extent that it would result in the Reporting Persons owning more than 9.99% of the Common Stock outstanding.
• The percentage is calculated based on 103,796,406 shares of Common Stock outstanding as of November 13, 2024 (as reported by the Issuer in its Form 10-Q) plus the 11,520,120 shares currently issuable under the blocker.
• The Reporting Persons explicitly disclaim status as a "group" for the purposes of this Schedule 13G.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing itself is a routine disclosure. The continued significant passive stake by a reputable investor like RA Capital Management can be seen as a positive signal of long-term interest, but it provides no new operational or financial performance data.

Positives

• A significant institutional investor, RA Capital Management, maintains a substantial passive stake (9.9%) in Unicycive Therapeutics, indicating continued investment interest.
• The presence of a beneficial ownership blocker suggests a structured investment approach that manages control-related reporting thresholds, which can be viewed as a stable, long-term passive investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Unicycive Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• The document contains no direct quotes or paraphrased statements from Unicycive Therapeutics, Inc. management. It includes certifications from the Reporting Persons stating the securities were not acquired for the purpose of changing or influencing control of the issuer.

Industry Context

This Schedule 13G/A filing primarily concerns an institutional investor's passive stake and does not provide specific details on Unicycive Therapeutics, Inc.'s industry position or broader industry trends. However, RA Capital Management is a prominent healthcare-focused investment firm, suggesting Unicycive Therapeutics operates within the biotechnology or pharmaceutical sectors, where such passive investments are common.

Comparison to Industry Standards

• This filing is a standard beneficial ownership disclosure (Schedule 13G/A) by a passive investor.
• It does not contain performance metrics or operational results that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The 9.9% ownership stake is a significant, but passive, position for an institutional investor in a public company.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which could be viewed positively as a vote of confidence. The beneficial ownership blocker limits potential dilution from conversion of preferred stock beyond 9.99% at any given time.

Key Dates

Keywords

Unicycive Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Warrants, Institutional Investor